Sort
82,697 grants matching “vaccine development”
MBRS SCORE Program at UPR, Medical Sciences Campus
$706,916University Of Puerto Rico Med Sciences · S06 · FY2002 · GM
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.
$706,887Michael S. Diamond · Washington University · R01 · FY2023 · AI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
$706,868Christopher L King · Case Western Reserve University · R01 · FY2023 · AI
Human Antibodies to HIV-1 by Repertoire Cloning
$706,835Dennis R. Burton · Scripps Research Institute, The · R01 · FY2012 · AI
Phase 1 Trial of Na-APR-1 and Na-GST-1 Hookworm Vaccines in Brazilian Adults
$706,806David Joseph Diemert · George Washington University · U01 · FY2017 · AI
A universal malaria T cell vaccine based on HLA-E presentation
$706,784Brandon Keith Wilder · Oregon Health & Science University · R01 · FY2025 · AI
Syphilis Immunology and Biology to Improve Clinical Management and Vaccine Design
$706,759Jeffrey David Klausner · University Of Southern California · R01 · FY2024 · AI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
$706,742Christopher L King · Case Western Reserve University · R01 · FY2022 · AI
Evaluation of Protective Immunity After Mucosal Vaccination Against Ebola Virus
$706,731Maria A Croyle · University Of Texas At Austin · U01 · FY2011 · AI
Small Molecule Inhibitors of Ebola Virus Infection
$706,701James M Cunningham · Harvard Medical School · U19 · FY2018 · AI
Pre-Exposure Prophylaxis Against Francisella tularensis
$706,654Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2014 · AI
Pre-Exposure Prophylaxis Against Francisella tularensis
$706,654Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2015 · AI
Pre-Exposure Prophylaxis Against Francisella tularensis
$706,654Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2016 · AI
A Vaccine for Schistosomiasis, "SchistoShield"
$706,627Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2020 · AI
New Paradigms in Gene Regulation During Influenza Virus Infections
$706,543Curt M Horvath · Northwestern University · U01 · FY2012 · AI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
$706,539Christopher D Vanderwal · University Of California-Irvine · R01 · FY2021 · AI
Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana
$706,524Steffanie A Strathdee · University Of California, San Diego · R01 · FY2008 · DA
Immune responses to VSV/HIV/SIV Hybrids in Macaques
$706,501John Rose · Yale University · R01 · FY2010 · AI
Early life B cell responses and inflammation following SARS-CoV-2 infection
$706,463Genevieve Giny Fouda Amou Ou · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI
Carbohydrate Antigen-bearing Nanoparticles for Antitumor Therapy
$706,429Joseph John Barchi · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Natural Killer cells and the Immunogenetics of COVID-19
$706,411Paul John Norman · University Of Colorado Denver · R01 · FY2024 · AI
Urban Water Systems, Enteric Pathogen Distribution & Gut Microbiome Development in Children: A Natural Experiment in Mozambique
$706,406Matthew C Freeman · Emory University · R01 · FY2021 · AI
Human M Cells Require Coronin 1a
$706,382Nicholas Constantine Zachos · Vanderbilt University Medical Center · R01 · FY2024 · AI
LINKING ANTIGENIC & GENETIC VARIATION OF DENGUE TO INDIVIDUAL AND POPULATION RISK
$706,331Derek A Cummings · University Of Florida · R01 · FY2017 · AI
Host and parasite factors influencing P. vivax RBC invasion and asexual development
$706,316David Serre · University Of Maryland Baltimore · R01 · FY2023 · AI